Pacira Pharmaceuticals, Inc.

10450 Science Center Drive
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Company Overview

Webcast ImageWebcast
Pacira Pharmaceuticals, Inc. at Bank of America Merrill Lynch Health Care Conference (Replay)
05/17/12 at 10:40 a.m. PT
Pacira Pharmaceuticals, Inc. at Bank of America Merrill Lynch Health Care Conference
Thursday, May 17, 2012 10:40 a.m. PT  
Webcast PresentationHelp Help
Click here for webcast
Add to CalendarHelp Help
Add to Calendar Click here to add this event to your calendar
Corporate Profile
Pacira Pharmaceuticals, Inc. is an emerging specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam® drug delivery technology, for use in hospitals and ambulatory surgery centers.
Stock Quote
PCRX (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$9.94
Change (%) Stock is Down 0.59 (5.60%)
Volume204,259
Data as of 05/17/12 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
Recent NewsMore >>
DateTitle 
05/10/12Pacira Pharmaceuticals, Inc. to Present at Bank of America Merrill Lynch 2012 Health Care Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 10, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that James Scibetta, chief financial officer of Pacira Pharmaceuticals, is scheduled to present at the Bank of America Merrill Lynch 2012 Health Care Conference on Thursday, May 17, 2012, at 10:40 a.m. PT at The Encore at Wynn in Las Vegas. Mr. Scibetta is expected to present an overview of the company. A live audio web... 
Printer Friendly Version
05/09/12Pacira Pharmaceuticals, Inc. Reports First Quarter 2012 Financial Results
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 9, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced consolidated financial results for the quarter ended March 31, 2012 and reviewed recent accomplishments, including the commercial launch in the United States of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain and the successful completion of an equ... 
Printer Friendly Version
05/03/12Pacira Pharmaceuticals, Inc. Completes $27.5 Million Debt Refinancing
Terms Defer Principal Repayment and Lock In Lower Interest Rate PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 3, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that it has secured a $27.5 million debt financing facility through Oxford Finance. Pacira will use the proceeds from this financing to refinance the remaining principal of its outstanding term loan and for general corporate purposes. The refinancing allows Pacira t... 
Printer Friendly Version
05/02/12Pacira Pharmaceuticals, Inc. Announces Timing for First Quarter 2012 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--May. 2, 2012-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that financial results for the company's first quarter ended March 31, 2012, will be released before the market opens on Wednesday, May 9, 2012. The Pacira management team will host a conference call to discuss the company's financial results and recent and upcoming developments on Wednesday, May 9, 2012, at 9 a.m. ET. The call can be ... 
Printer Friendly Version
Upcoming EventsMore >>
There are currently no events scheduled.
Receive E-mail AlertsE-mail Alert Icon
Sign up to receive e-mail alerts whenever Pacira Pharmaceuticals, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
 

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.